Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
|Articles|November 1, 2012
Dose optimization augments benefits of biologics for psoriasis
Dose optimization, including appropriate use of a loading dose regimen, weight-based dosing and adherence to routine maintenance treatment, will maximize the benefits of biologic therapy for chronic plaque psoriasis. But if disease improvement seems less than optimal despite proper dosing, dermatologists should not to give up too soon.
Advertisement
Advertisement
Related to this article
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Galderma has agreed to acquire ZO Skin Health for $1.5 billion, adding the physician-dispensed skincare brand to a portfolio that already includes Cetaphil and Alastin.
New dermatology research explores hidden steroids in OTC products, infant eczema, melanoma prevention, cutaneous lymphoma, and pediatric AD.
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
An analysis of 633 skincare brands found gaps in evidence, safety information, and claim support, raising questions about what patients can verify online.
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Oral PKM2 Modulator Shows Early Efficacy in Atopic Dermatitis
2
Alopecia Areata Is a Medical Disease: Treatment Options and Defining Severity
3
Galderma to Acquire ZO Skin Health for $1.5 Billion
4
AI-Era Skincare Report Finds Widespread Gaps in Verifiable Product Claims
5